EA202190267A1 - Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака - Google Patents

Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака

Info

Publication number
EA202190267A1
EA202190267A1 EA202190267A EA202190267A EA202190267A1 EA 202190267 A1 EA202190267 A1 EA 202190267A1 EA 202190267 A EA202190267 A EA 202190267A EA 202190267 A EA202190267 A EA 202190267A EA 202190267 A1 EA202190267 A1 EA 202190267A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dendritic cells
compositions
methods
cancer therapy
recombinant dendritic
Prior art date
Application number
EA202190267A
Other languages
English (en)
Inventor
Серхат Гумруксу
Original Assignee
Инокиан Байофарма, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инокиан Байофарма, Инк. filed Critical Инокиан Байофарма, Инк.
Publication of EA202190267A1 publication Critical patent/EA202190267A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0639Dendritic cells, e.g. Langherhans cells in the epidermis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49Breast
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50Colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464402Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429Molecules with a "CD" designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464499Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении раскрыты способы и композиции для лечения рака посредством индукции иммунного ответа путем введения дендритных клеток, экспрессирующих гетерологичные белки. В некоторых вариантах осуществления дендритная клетка включает одну или более гетерологичных молекул нуклеиновых кислот, кодирующих CD40L и CXCL13. В некоторых вариантах осуществления дендритная клетка дополнительно включает гетерологичную молекулу нуклеиновой кислоты, кодирующую CD93. В других дополнительных вариантах осуществления дендритные клетки, экспрессирующие гетерологичные белки, активированы.
EA202190267A 2018-07-15 2019-07-15 Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака EA202190267A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862698254P 2018-07-15 2018-07-15
PCT/US2019/041786 WO2020018413A1 (en) 2018-07-15 2019-07-15 Methods and compositions using recombinant dendritic cells for cancer therapy

Publications (1)

Publication Number Publication Date
EA202190267A1 true EA202190267A1 (ru) 2021-05-17

Family

ID=69138636

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190267A EA202190267A1 (ru) 2018-07-15 2019-07-15 Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака

Country Status (14)

Country Link
US (1) US11413338B2 (ru)
EP (1) EP3820486A4 (ru)
JP (1) JP7520806B2 (ru)
KR (1) KR20210044207A (ru)
CN (1) CN112703004A (ru)
AU (1) AU2019306504A1 (ru)
BR (1) BR112021000620A2 (ru)
CA (1) CA3106403A1 (ru)
EA (1) EA202190267A1 (ru)
IL (1) IL280145A (ru)
MX (1) MX2021000421A (ru)
SG (1) SG11202100315TA (ru)
WO (1) WO2020018413A1 (ru)
ZA (1) ZA202100234B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3143599A1 (en) * 2019-06-17 2020-12-24 Enochian BioPharma, Inc. Allogeneic t-cell-based hiv vaccine to induce cellular and humoral immunity
CN115605084A (zh) * 2020-01-31 2023-01-13 S·居姆吕克曲(Ca) 用于提供化学保护作用的组合物和方法
US20220249551A1 (en) * 2021-02-08 2022-08-11 Therapeutic Solutions International, Inc. Stimulation of natural kill cell memory by administration of dendritic cells
GB2625100A (en) 2022-12-06 2024-06-12 Reliance Worldwide Corporation Uk Ltd A plumbing connector

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109168A0 (en) 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US20030202963A1 (en) 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
WO2003045427A2 (en) * 2001-11-29 2003-06-05 Dandrit Biotech A/S Pharmaceutical composition for inducing an immune response in a human or animal
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
WO2006031870A2 (en) 2004-09-14 2006-03-23 Argos Therapeutics, Inc. Strain independent amplification of pathogens and vaccines thereto
CN101080487B (zh) * 2004-10-07 2012-11-14 阿戈斯治疗公司 成熟树突细胞组合物及其培养方法
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
NZ561211A (en) 2005-03-25 2011-03-31 Genentech Inc Methods and compositions for modulating hyperstabilized C-met
CN101155914B (zh) 2005-04-08 2013-03-06 阿戈斯治疗公司 树状细胞组合物和方法
WO2008055354A1 (en) * 2006-11-10 2008-05-15 Université de Montréal Rna-loaded dendritic cell compositions for eliciting cd4+ t cell help and related methods
EP2201100B1 (en) 2007-09-14 2016-03-16 Vrije Universiteit Brussel Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination
WO2009094456A2 (en) 2008-01-22 2009-07-30 Johns Hopkins University Use of high-dose, post-transplantation oxazaphosphorine drugs for reduction of transplant rejection
WO2009149539A1 (en) 2008-06-10 2009-12-17 Université de Montréal Enhancing antigen-specific cd8+ t cell response using irf-7 mrna
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CN102459575A (zh) 2009-06-05 2012-05-16 细胞动力国际有限公司 重编程t细胞和造血细胞的方法
RU2015133046A (ru) 2009-07-15 2018-12-24 Кэлиммьюн Инк. Двойной вектор для подавления вируса иммунодефицита человека
US9234175B2 (en) 2009-11-17 2016-01-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Creating bioengineered lymph nodes
GB201013443D0 (en) * 2010-08-11 2010-09-22 Cytovac As Compositions and methods for producing dendritic cells
WO2014121840A1 (en) 2013-02-07 2014-08-14 Medizinische Hochschule Hannover Induced dendritic cells and uses thereof
KR20160138177A (ko) 2014-03-21 2016-12-02 애브비 인코포레이티드 항-egfr 항체 및 항체 약물 접합체
CN104630145A (zh) * 2015-01-12 2015-05-20 杨世成 一种抗肿瘤t细胞、其制备方法和抗肿瘤药物
KR20230114331A (ko) 2016-09-14 2023-08-01 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
CN106701680A (zh) * 2016-11-30 2017-05-24 广州赛莱拉干细胞科技股份有限公司 一种促进树突状细胞成熟的组合因子及培养树突状细胞的方法

Also Published As

Publication number Publication date
WO2020018413A1 (en) 2020-01-23
JP2021531765A (ja) 2021-11-25
IL280145A (en) 2021-03-01
CN112703004A (zh) 2021-04-23
ZA202100234B (en) 2022-07-27
CA3106403A1 (en) 2020-01-23
AU2019306504A1 (en) 2021-03-11
BR112021000620A2 (pt) 2021-04-20
KR20210044207A (ko) 2021-04-22
EP3820486A4 (en) 2022-05-04
US20200016250A1 (en) 2020-01-16
EP3820486A1 (en) 2021-05-19
SG11202100315TA (en) 2021-02-25
US11413338B2 (en) 2022-08-16
MX2021000421A (es) 2021-05-12
JP7520806B2 (ja) 2024-07-23

Similar Documents

Publication Publication Date Title
EA202190267A1 (ru) Способы и композиции с использованием рекомбинантных дендритных клеток для терапии рака
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
CY1122800T1 (el) Συνθεσεις του παραγοντα viii και μεθοδοι δημιουργιας και χρησης αυτων
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JOP20200313A1 (ar) أجسام مضادة dll3-cd3 ثنائية الخاصية
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
SA522432139B1 (ar) بروتينات ربط متعددة الخصوصية لمعالجة السرطان
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
EA202090817A1 (ru) Триспецифические белки и способы их применения
PH12019500596A1 (en) Recombinant binding proteins and their use
PH12020551907A1 (en) Antagonizing cd73 antibody
MX2018013548A (es) Proteinas de union biespecificas y usos de las mismas.
PH12019500122A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
EA202092093A1 (ru) Композиции и способы перепрограммирования tcr с применением слитых белков
EA201892774A1 (ru) Антитела
MX2021008392A (es) Neoantígenos prostaticos y sus usos.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
MX2023010640A (es) Péptidos neoantigénicos transmembranales.
MX2020009550A (es) Proteinas de union a antigeno antagonistas.
PH12020551955A1 (en) Anti-cd63 antibodies, conjugates, and uses thereof
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения
EA202191919A1 (ru) Неоантигены предстательной железы и их применение
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения